Table S9. Estimation of *RAD50* rs11739623/rs4705959 haplotype frequency in patients treated with benralizumab.

	rs11739623	rs4705959	Freq	R	NR	Cumulative frequency	OR (95% CI)	p-value
Responsive for 1 criterion								
-	-	-	-	-	-	-	-	-
Responsive for 2 criteria								
1	C	T	0.7255	0.7262	0.7222	0.7255	1.00	---
2	T	C	0.2451	0.2381	0.2778	0.9706	1.12 (0.35 - 3.60)	0.85
3	T	T	0.0294	0.0357	NA	1	0.00 (-Inf - Inf)	1
Global haplotype association p-value: 0.54								
Responsive for 3 criteria								
1	C	T	0.7255	0.78	0.6731	0.7255	1.00	---
2	T	C	0.2451	0.16	0.3269	0.9706	2.28 (0.83 - 6.28)	0.12
3	T	T	0.0294	0.06	NA	1	0.00 (-Inf - Inf)	1
Global haplotype association p-value: 0.027								
Reduction in OCS ≥ 50%								
1	C	T	0.7255	0.7656	0.6579	0.7255	1.00	---
2	T	C	0.2451	0.1875	0.3421	0.9706	2.07 (0.78 - 5.48)	0.15
3	T	T	0.0294	0.0469	NA	1	0.00 (-Inf - Inf)	1
Global haplotype association p-value: 0.076								
Reduction in exacerbations ≥ 50%								
1	C	T	0.7255	0.7188	0.8333	0.7255	1.00	---
2	T	C	0.2451	0.25	0.1667	0.9706	0.54 (0.06 - 5.02)	0.59
3	T	T	0.0294	0.0312	NA	1	0.00 (-Inf - Inf)	1
Global haplotype association p-value: 0.7								
Increase in %FEV1 ≥ 10% or %FEV1 ≥ 80%								
1	C	T	0.7255	0.7297	0.7143	0.7255	1.00	---
2	T	C	0.2451	0.2297	0.2857	0.9706	1.21 (0.44 - 3.29)	0.72
3	T	T	0.0294	0.0405	NA	1	0.00 (-Inf - Inf)	1
Global haplotype association p-value: 0.34								

Freq: haplotype frequency; NA, not available; R, responder; NR, non-responder.